Background: Metabolic syndrome is associated with increased risk for both type 2 diabetesand cardiovascular disease. Development of these pathologies is associated with the disorders of lipidand lipoprotein metabolism. Dyslipidemia leads to the overproduction of potentially atherogenic lipidand lipoproteins. Furthermore, there is a decrease in the levels of high-density lipoproteins and anincrease in the levels of remnant and small dense LDL particles.Conclusion: In the current review, we have discussed the pathophysiology of lipoprotein biosynthesisand metabolism in the metabolic syndrome. Finally, we describe regulation of lipoprotein metabolismwhich may be used as a potential target for treating dyslipidemia in metabolic syndrome.
展开▼
